Control Bionics Limited (CBL.AX)
- Previous Close
0.0430 - Open
0.0430 - Bid 0.0430 x 510900
- Ask 0.0510 x 1063200
- Day's Range
0.0430 - 0.0430 - 52 Week Range
0.0330 - 0.1443 - Volume
26,067 - Avg. Volume
32,890 - Market Cap (intraday)
7.339M - Beta (5Y Monthly) -0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date Apr 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.06
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; NeuroNode Duo, a wireless sensor; and Eye gaze Duo that allows the user to control a computer mouse with their eyes. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Camberwell, Australia.
www.controlbionics.comRecent News: CBL.AX
Performance Overview: CBL.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CBL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CBL.AX
Valuation Measures
Market Cap
7.34M
Enterprise Value
6.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.80
Price/Book (mrq)
0.95
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
-1.41
Financial Highlights
Profitability and Income Statement
Profit Margin
-84.45%
Return on Assets (ttm)
-28.64%
Return on Equity (ttm)
-55.33%
Revenue (ttm)
5.71M
Net Income Avi to Common (ttm)
-4.82M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.31M
Total Debt/Equity (mrq)
1.02%
Levered Free Cash Flow (ttm)
-2.43M
Research Analysis: CBL.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: CBL.AX
CBL.AX does not have Company Insights